Medicare Program: Notice of Six Membership Appointments to the Advisory Panel on Hospital Outpatient Payment, 9255-9256 [2012-3643]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 32 / Thursday, February 16, 2012 / Notices
free: 1–800–CDC–INFO, email:
dcas@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
Notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: February 7, 2012.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2012–3587 Filed 2–15–12; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–1594–N]
Medicare Program: Notice of Six
Membership Appointments to the
Advisory Panel on Hospital Outpatient
Payment
Centers for Medicare &
Medicaid Services (CMS), Department
of Health and Human Services (HHS).
ACTION: Notice.
AGENCY:
This notice announces six
new membership appointments to the
Advisory Panel on Hospital Outpatient
Payment (HOP, the Panel). The six
appointments to the 19 member Panel
will each serve a 4-year period. Five of
the new members will have terms that
begin on February 1, 2012 and
continuing through January 31, 2016.
The sixth member’s term will begin on
August 1, 2012 and continuing through
July 31, 2016. The purpose of the Panel
is to advise the Secretary of the
Department of Health and Human
Services and the Administrator of the
Centers for Medicare & Medicaid
Services concerning the clinical
integrity of the Ambulatory Payment
Classification groups and their weights.
The Panel also addresses and makes
recommendations regarding supervision
of outpatient services. The advice
provided by the Panel will be
considered as we prepare the annual
updates for the hospital outpatient
prospective payment system.
FOR FURTHER INFORMATION CONTACT: For
additional information on the Panel
meeting dates, agenda topics, copy of
the charter, as well as updates to the
Panel’s activities, search our Internet
srobinson on DSK4SPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
16:31 Feb 15, 2012
Jkt 226001
Web site: https://www.cms.gov/FACA/
05_AdvisoryPanelonAmbulatory
PaymentClassification
Groups.asp#TopOfPage. (Note: There is
an UNDERSCORE after FACA/05_; there
is no space.)
For other information regarding the
Panel, contact Paula Smith, the
Designated Federal Officer at CMS,
Center for Medicare, Hospital and
Ambulatory Policy Group, Division of
Outpatient Care, 7500 Security
Boulevard, Mail Stop C4–05–13,
Baltimore, MD 21244–1850, phone (410)
786–4709. Information can also be
obtained by contacting the CMS
Advisory Committees’ Information Line
at 1–877–449–5659 (toll free) and (410)
786–9379 (local).
SUPPLEMENTARY INFORMATION:
I. Background
The Secretary of the Department of
Health and Human Services (the
Secretary) is required by section
1833(t)(9)(A) of the Social Security Act
(the Act) (42 U.S.C. 1395l(t)(9)(A)) and
section 222 of the Public Health Service
Act (PHS Act) (42 U.S.C. 217a) to
consult with an expert outside advisory
panel on the clinical integrity of the
Ambulatory Payment Classification
groups and weights. The Advisory Panel
on Hospital Outpatient Payment (HOP,
the Panel) is governed by the provisions
of the Federal Advisory Committee Act
(FACA) (Pub. L. 92–463, as amended (5
U.S.C. Appendix 2), which sets forth
standards for the formation and use of
advisory panels. The Panel Charter
provides that the Panel shall meet up to
3 times annually. We consider the
technical advice provided by the Panel
as we prepare the proposed and final
rules to update the outpatient
prospective payment system for the next
calendar year.
The Panel shall consist of a chair and
up to 19 members who are full-time
employees of hospitals, hospital
systems, or other Medicare providers.
The Secretary or a designee selects the
Panel membership based upon either
self-nominations or nominations
submitted by Medicare providers and
other interested organizations. New
appointments are made in a manner that
ensures a balanced membership under
the FACA guidelines.
The Panel presently consists of the
following members and a Chair: (The
asterisk [*] indicates a Panel member
whose term expires on July 31, 2012).
• Edith Hambrick, M.D., J.D., Chair,
CMS Medical Officer.
• Ruth L. Bush, M.D., M.P.H.
• Kari S. Cornicelli, C.P.A., FHFMA.
• Dawn L. Francis, M.D., M.H.S.
• Kathleen Graham, R.N., M.S.H.A.*
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
9255
• David A. Halsey, M.D.
• Brian D. Kavanagh, M.D., MPH.
• Judith T. Kelly, R.H.I.T., R.H.I.A.,
C.C.S.
• Scott Manaker, M.D., Ph.D.
• John Marshall, CRA, RCC, CIRCC,
RT(R), FAHRA.
• Jacqueline Phillips.
• Randall A. Oyer, M.D.
• Daniel J. Pothen, M.S., RHIA, CHPS.
• Gregory Przybylski, M.D.
• Marianna V. Spanaki-Varela, MD,
Ph.D., M.B.A.
II. Provisions of the Notice
We published a notice in the Federal
Register on November 25, 2011, entitled
‘‘Medicare Program; Renaming and
Other Changes to the Advisory Panel on
Hospital Outpatient Payment Charter
(Formerly the Advisory Panel on
Ambulatory Payment Classification
Groups) and Request for Nominations’’
(76 FR 72708). The notice requested
nominations to be added to the Panel by
replacing one Panel member whose term
expires on July 31, 2012; replacing one
Panel member who resigned; and by
adding four new Panel members (two of
these designated as Critical Access
Hospital representatives (see the
November 30, 2011 final rule, (76 FR
74363)) to address appropriate
supervision level for hospital outpatient
services. As a result of that November
25, 2012 notice and the November 30,
2011 final rule, we are announcing six
new members to the Panel. Their
appointments are for 4-year terms
commencing on February 1, 2012 and
August 1, 2012.
New Appointments to the Panel—The
new members of the Panel with terms
beginning on February 1, 2012 and
continuing through January 31, 2016 are
as follows:
• Lanny Copeland, M.D.,
• Jim Nelson,
• Leah Osbahr,
• Traci Rabine; and
• Gale Walker
The new member of the Panel with a
term beginning on August 1, 2012, and
continuing through July 31, 2016 is:
• Karen Borman, M.D.
III. Collection of Information
Requirements
This document does not impose
information collection and
recordkeeping requirements.
Consequently, it need not be reviewed
by the Office of Management and
Budget under the authority of the
Paperwork Reduction Act of 1995 (44
U.S.C. 35).
(Catalog of Federal Domestic Assistance
Program; No. 93.773 Medicare—Hospital
Insurance Program; and No. 93.774,
E:\FR\FM\16FEN1.SGM
16FEN1
9256
Federal Register / Vol. 77, No. 32 / Thursday, February 16, 2012 / Notices
Medicare—Supplementary Medical
Insurance Program)
Section 1833(t)(9)(A) of the Act (42 U.S.C.
1395l(t)(9)(A)). The Panel is governed by the
provisions of the Federal Advisory
Committee Act, as amended (5 U.S.C.
Appendix 2).
Dated: February 8, 2012.
Marilyn Tavenner,
Acting Administrator, Centers for Medicare
& Medicaid Services.
[FR Doc. 2012–3643 Filed 2–15–12; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–N–0123]
Design and Methodology for
Postmarket Surveillance Studies Under
Section 522 of the Federal Food, Drug,
and Cosmetic Act; Public Workshop
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public workshop.
The Food and Drug
Administration (FDA) is announcing a
public workshop entitled ‘‘Design and
Methodology for Postmarket
Surveillance Studies under Section 522
of the Federal Food, Drug and Cosmetic
Act’’. The purpose of the public
workshop is to provide a forum for
discussion among FDA, industry,
governmental agencies, academia,
clinicians and various stakeholders with
experience in epidemiology, statistics,
and biomedical research to advance the
design and methodologies for medical
device surveillance studies in the
‘‘postmarket’’ setting, i.e., after FDA
premarket approval or clearance of the
device and marketing of the device has
begun.
DATES: The meeting will be held on
March 7, 2012, from 8 a.m. to 5:30 p.m.
ADDRESSES: The meeting will be held at
the FDA White Oak Campus, 10903
New Hampshire Ave., Bldg. 31, Rm
1503 (the Great Room), Silver Spring,
MD 20993. For parking and security
information, please visit the following
Web site: https://www.fda.gov/
AboutFDA/WorkingatFDA/
BuildingsandFacilities/
WhiteOakCampusInformation/
ucm241740.htm. The public workshop
will also be available to be viewed
online via webcast.
FOR FURTHER INFORMATION CONTACT:
Samantha Jacobs, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
srobinson on DSK4SPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
16:31 Feb 15, 2012
Jkt 226001
Ave., Bldg. 66, Rm. 4201C, Silver
Spring, MD 20993, 301–796–6897,
email: samantha.jacobs@fda.hhs.gov; or
Mary Beth Ritchey, Center for Devices
and Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 4118, Silver Spring,
MD 20993, 301–796–6638, email:
maryelizabeth.ritchey@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
Registration: To register for the public
workshop, please visit the following
Web site: https://www.fda.gov/
MedicalDevices/NewsEvents/
WorkshopsConferences/ucm289465.htm
(or go to https://www.fda.gov and select
the FDA Medical Devices News &
Events—Workshops & Conferences
calendar and select this public
workshop from the posted events list).
Please provide complete contact
information for each attendee, including
name, title, affiliation, address, email,
and telephone number. For persons
interested in attending this workshop
and without Internet access, please call
one of the people listed in the FOR
FURTHER INFORMATION CONTACT section
in this document in order to register.
Registrants will receive confirmation
once they have been accepted. You will
be notified if you are on a waitlist.
There is no fee to attend the public
workshop, but attendees must register in
advance. Registration will be on a firstcome, first-served basis. Persons
interesting in attending this workshop
must register online by February 29,
2012. Registration is mandatory as space
is limited and onsite registration will
not be available. FDA may limit the
number of participants from each
organization.
If you need special accommodations
due to a disability, please contact Susan
Monahan at
susan.monahan@fda.hhs.gov no later
than March 1, 2012.
Security: Non-U.S. citizens are subject
to additional security screening, and
they should register as soon as possible.
Entrance for the public meeting
participants (non-FDA employees) is
through Building 1 where routine
security check procedures will be
performed. For parking and security
information, please visit the Web site
address in the ADDRESSES section of this
document.
Streaming Webcast of the Public
Workshop: This workshop will also be
webcast. Persons interested in viewing
the webcast must register online by 5
p.m. on February 29, 2012. Early
registration is recommended because
webcast connections are limited.
Organizations are requested to register
all participants, but view using one
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
connection per location. Webcast
participants will be sent technical
system requirements after registration,
and will be sent connection access
information after March 1, 2012. If you
have never attended a Connect Pro
meeting before, test your connection at:
https://collaboration.fda.gov/common/
help/en/support/meeting_test.htm. To
get a quick overview of the Connect Pro
program, visit: https://www.adobe.com/
go/connectpro_overview. (FDA has
verified the Web site addresses in this
document, but FDA is not responsible
for any subsequent changes to the Web
sites after this document publishes in
the Federal Register.)
Background: Under section 522(a) of
the Federal Food, Drug and Cosmetic
Act (FD&C Act), enacted by the Food
and Drug Administration Modernization
Act of 1997 (FDAMA) (Pub. L. 105–115,
§ 212, 111 Stat. 2346), codified at 21
U.S.C. 360l(a), FDA may order a
manufacturer to conduct postmarket
surveillance for any Class II or Class III
device (i) Intended to be implanted in
the human body for more than 1 year or
to be used to sustain or support life
outside a device user facility, or (ii)
whose failure would be reasonably
likely to have serious adverse health
consequences. The Food and Drug
Administration Amendments of 2007
(FDAAA) (Pub. L. 110–85, § 307, 121
Stat. 865) expanded the scope of section
522 to include devices intended for
pediatric use.
Agenda for the Public Workshop
1. Why are we holding this public
workshop?
The purpose of the proposed
workshop is to facilitate discussion
among the FDA, industry, governmental
agencies, academia, clinicians, and key
stakeholders with experience in
epidemiology, statistics, and biomedical
research in the scientific community to
advance the design and methodologies
for medical device surveillance studies
in the postmarket setting.
2. Who is the target audience for this
public workshop? Who should attend
this public workshop?
This workshop is open to all
interested parties. The target audience is
professionals in the scientific
community interested in advancing the
infrastructure and methodology for
postmarket surveillance studies.
3. What are the topics we intend to
address at the public workshop?
We intend to discuss a large number
of issues at the workshop, including, but
not limited to the following:
E:\FR\FM\16FEN1.SGM
16FEN1
]]>Agencies
[Federal Register Volume 77, Number 32 (Thursday, February 16, 2012)]
[Notices]
[Pages 9255-9256]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-3643]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS-1594-N]
Medicare Program: Notice of Six Membership Appointments to the
Advisory Panel on Hospital Outpatient Payment
AGENCY: Centers for Medicare & Medicaid Services (CMS), Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces six new membership appointments to the
Advisory Panel on Hospital Outpatient Payment (HOP, the Panel). The six
appointments to the 19 member Panel will each serve a 4-year period.
Five of the new members will have terms that begin on February 1, 2012
and continuing through January 31, 2016. The sixth member's term will
begin on August 1, 2012 and continuing through July 31, 2016. The
purpose of the Panel is to advise the Secretary of the Department of
Health and Human Services and the Administrator of the Centers for
Medicare & Medicaid Services concerning the clinical integrity of the
Ambulatory Payment Classification groups and their weights. The Panel
also addresses and makes recommendations regarding supervision of
outpatient services. The advice provided by the Panel will be
considered as we prepare the annual updates for the hospital outpatient
prospective payment system.
FOR FURTHER INFORMATION CONTACT: For additional information on the
Panel meeting dates, agenda topics, copy of the charter, as well as
updates to the Panel's activities, search our Internet Web site:
https://www.cms.gov/FACA/05_AdvisoryPanelonAmbulatoryPaymentClassificationGroups.asp#TopOfPage.
(Note: There is an UNDERSCORE after FACA/05--; there is no space.)
For other information regarding the Panel, contact Paula Smith, the
Designated Federal Officer at CMS, Center for Medicare, Hospital and
Ambulatory Policy Group, Division of Outpatient Care, 7500 Security
Boulevard, Mail Stop C4-05-13, Baltimore, MD 21244-1850, phone (410)
786-4709. Information can also be obtained by contacting the CMS
Advisory Committees' Information Line at 1-877-449-5659 (toll free) and
(410) 786-9379 (local).
SUPPLEMENTARY INFORMATION:
I. Background
The Secretary of the Department of Health and Human Services (the
Secretary) is required by section 1833(t)(9)(A) of the Social Security
Act (the Act) (42 U.S.C. 1395l(t)(9)(A)) and section 222 of the Public
Health Service Act (PHS Act) (42 U.S.C. 217a) to consult with an expert
outside advisory panel on the clinical integrity of the Ambulatory
Payment Classification groups and weights. The Advisory Panel on
Hospital Outpatient Payment (HOP, the Panel) is governed by the
provisions of the Federal Advisory Committee Act (FACA) (Pub. L. 92-
463, as amended (5 U.S.C. Appendix 2), which sets forth standards for
the formation and use of advisory panels. The Panel Charter provides
that the Panel shall meet up to 3 times annually. We consider the
technical advice provided by the Panel as we prepare the proposed and
final rules to update the outpatient prospective payment system for the
next calendar year.
The Panel shall consist of a chair and up to 19 members who are
full-time employees of hospitals, hospital systems, or other Medicare
providers. The Secretary or a designee selects the Panel membership
based upon either self-nominations or nominations submitted by Medicare
providers and other interested organizations. New appointments are made
in a manner that ensures a balanced membership under the FACA
guidelines.
The Panel presently consists of the following members and a Chair:
(The asterisk [*] indicates a Panel member whose term expires on July
31, 2012).
Edith Hambrick, M.D., J.D., Chair, CMS Medical Officer.
Ruth L. Bush, M.D., M.P.H.
Kari S. Cornicelli, C.P.A., FHFMA.
Dawn L. Francis, M.D., M.H.S.
Kathleen Graham, R.N., M.S.H.A.*
David A. Halsey, M.D.
Brian D. Kavanagh, M.D., MPH.
Judith T. Kelly, R.H.I.T., R.H.I.A., C.C.S.
Scott Manaker, M.D., Ph.D.
John Marshall, CRA, RCC, CIRCC, RT(R), FAHRA.
Jacqueline Phillips.
Randall A. Oyer, M.D.
Daniel J. Pothen, M.S., RHIA, CHPS.
Gregory Przybylski, M.D.
Marianna V. Spanaki-Varela, MD, Ph.D., M.B.A.
II. Provisions of the Notice
We published a notice in the Federal Register on November 25, 2011,
entitled ``Medicare Program; Renaming and Other Changes to the Advisory
Panel on Hospital Outpatient Payment Charter (Formerly the Advisory
Panel on Ambulatory Payment Classification Groups) and Request for
Nominations'' (76 FR 72708). The notice requested nominations to be
added to the Panel by replacing one Panel member whose term expires on
July 31, 2012; replacing one Panel member who resigned; and by adding
four new Panel members (two of these designated as Critical Access
Hospital representatives (see the November 30, 2011 final rule, (76 FR
74363)) to address appropriate supervision level for hospital
outpatient services. As a result of that November 25, 2012 notice and
the November 30, 2011 final rule, we are announcing six new members to
the Panel. Their appointments are for 4-year terms commencing on
February 1, 2012 and August 1, 2012.
New Appointments to the Panel--The new members of the Panel with
terms beginning on February 1, 2012 and continuing through January 31,
2016 are as follows:
Lanny Copeland, M.D.,
Jim Nelson,
Leah Osbahr,
Traci Rabine; and
Gale Walker
The new member of the Panel with a term beginning on August 1,
2012, and continuing through July 31, 2016 is:
Karen Borman, M.D.
III. Collection of Information Requirements
This document does not impose information collection and
recordkeeping requirements. Consequently, it need not be reviewed by
the Office of Management and Budget under the authority of the
Paperwork Reduction Act of 1995 (44 U.S.C. 35).
(Catalog of Federal Domestic Assistance Program; No. 93.773
Medicare--Hospital Insurance Program; and No. 93.774,
[[Page 9256]]
Medicare--Supplementary Medical Insurance Program)
Section 1833(t)(9)(A) of the Act (42 U.S.C. 1395l(t)(9)(A)). The
Panel is governed by the provisions of the Federal Advisory
Committee Act, as amended (5 U.S.C. Appendix 2).
Dated: February 8, 2012.
Marilyn Tavenner,
Acting Administrator, Centers for Medicare & Medicaid Services.
[FR Doc. 2012-3643 Filed 2-15-12; 8:45 am]
BILLING CODE 4120-01-P
